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Abstract: As tool compounds to study cardiac ischemia, the endogenous δ-opioid receptors
(δOR) agonist Leu5-enkephalin and the more metabolically stable synthetic peptide (d-Ala2,
d-Leu5)-enkephalin are frequently employed. However, both peptides have similar pharmacological
profiles that restrict detailed investigation of the cellular mechanism of the δOR’s protective role
during ischemic events. Thus, a need remains for δOR peptides with improved selectivity and
unique signaling properties for investigating the specific roles for δOR signaling in cardiac ischemia.
To this end, we explored substitution at the Phe4 position of Leu5-enkephalin for its ability to
modulate receptor function and selectivity. Peptides were assessed for their affinity to bind to δORs
and µ-opioid receptors (µORs) and potency to inhibit cAMP signaling and to recruit β-arrestin
2. Additionally, peptide stability was measured in rat plasma. Substitution of the meta-position
of Phe4 of Leu5-enkephalin provided high-affinity ligands with varying levels of selectivity and
bias at both the δOR and µOR and improved peptide stability, while substitution with picoline
derivatives produced lower-affinity ligands with G protein biases at both receptors. Overall, these
favorable substitutions at the meta-position of Phe4 may be combined with other modifications
to Leu5-enkephalin to deliver improved agonists with finely tuned potency, selectivity, bias and
drug-like properties.
Keywords: Leu-enkephalin; beta-arrestin; mu opioid receptor; delta opioid receptor; biased signaling;
DADLE; ischemia; plasma stability
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1. Introduction
Leu5-enkephalin (Tyr1-Gly2-Gly3-Phe4-Leu5, Figure 1) is an endogenous opioid peptide produced
in vertebrate species including rodents, primates and humans [1–4] that results from the metabolism of
proenkephalin or dynorphin [5]. Pharmacologically, Leu5-enkephalin agonizes the δ opioid receptor
(δOR) with moderate selectivity over the µ opioid receptor (µOR), but does not significantly interact
with the κ opioid receptor [6]. As a neurotransmitter in pain circuits, Leu5-enkephalin possesses
antinociceptive properties [7], whereas peripherally, the peptide demonstrates cardiovascular effects [8].
Over the last two decades, improved pharmacological characterization of opioid pathways has
revealed that activation of an opioid receptor can trigger two distinct pathways, β-arrestin-dependent
or β-arrestin-independent (i.e., G protein-mediated) and that these pathways differentially modulate
antinociception and side effect profiles [9]. Despite the increasing number of studies that implicate
δOR mediated β-arrestin recruitment with various (patho)physiological effects, such as tolerance [10],
alcohol intake [11,12] and δOR agonist-induced seizures [10], the role of β-arrestin recruitment towards
δOR-induced cardioprotection remains unclear.
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apparent that DADLE pharmacologically signals similarly to Leu5-enkephalin, though it recruits β-
arrestin 2 (arrestin 3) slightly more efficaciously. Given the similarities between DADLE and Leu5-
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desired; however, reports of δOR selective peptide-based biased ligands remain limited. Recently,
the naturally occurring peptides rubiscolin-5 and -6 (Figure 1) were classified as G protein-biased
(β-arrestin 2 efficacy = 15% and 20%, respectively; δOR bias factor = 2.0) δOR selective peptides, albeit
with only micromolar potencies [22]. While a number of synthetic peptides display nanomolar potencies
at δORs, such as aza-β-homoleucine-enkephalin (β-arrestin 2 efficacy = 64%; δOR bias factor = 5.2) [23]
and Dmt-Tic analogs [24], these peptides all recruitβ-arrestin 2 far more efficaciously than the rubiscolins
(UFP-512: cAMP potency 0.4 nM, β-arrestin 2 potency = 20 nM, efficacy = 60%) [23–25]. Additionally,
these latter biased compounds, including aza-β-homoleucine-enkephalin and Dmt-Tic-Gly-NH-Ph,
have at best 10-fold selectivity for δORs overµORs and actually super-recruitβ-arrestin 2 atµOR [23,24],
which is likely to cause adverse, undesired in vivo effects [26,27]. As such, our goal was to identify
novel and potent δOR peptide agonists with varying degrees of β-arrestin recruitment efficacy, and that
importantly have improved δOR selectivity over µOR while limiting β-arrestin recruitment at µOR.
A collection of previously published structure activity relationship studies on Leu5-enkephalin
directed us to Phe4 as a position that can modulate δOR andµOR potency and selectivity (Figure 2A) [28].
Specifically, ortho and para substitutions on Phe4 can modulate binding affinity and selectivity between
opioid receptors [28], and halogenation of the para-position of Leu5-enkephalin and endomorphin 1 in
particular appears to enhance δOR affinity while reducing µOR affinity [28]. Corroborating research has
further shown that halogenation of the para position of Phe4 of [D-Pen2,D-Pen5]enkephalin (DPDPE)
enhanced δOR selectivity, potency, peptide stability, central nervous system (CNS) distribution, and
antinociceptive potency compared to unsubstituted DPDPE [29–31]. Thus, halogenation at Phe4 may
provide Leu5-enkephalin derivatives that can be used to study not only cardiac but also cerebral
ischemia [32,33]. We herein report structure-activity-relationship trends at the meta-position of Phe4
of Leu5-enkephalin (Figure 2B), demonstrating that substitution at this position variously regulates
δOR and µOR affinity and G-protein activity, enables the fine-tuning of β-arrestin 2 recruitment to
both δOR and µOR, and further increases the plasma stability of the derived peptides. Combined,
these features provide a clear direction for designing the next-generation of Leu5-enkephalin analogs
with well-defined biases and improved stabilities.
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2. Results and iscussion
2.1. Design Considerations
To probe the meta position of Phe4, we initially considered known structure-activity-relationship
trends at the ortho and para positions of this residue. Considering that halogenated substituents at these
positions perturbed binding affinity, δOR selectivity, and stability properties of the Leu5-enkephalin [28],
we initially hypothesized that meta-halogenated analogs might similarly perturb the parent scaffold
(Figure 3A, 1a–1d). An additional set of analogs bearing electron-donating (1e–1f) and -withdrawing
groups (1g–1i) would further probe interactions at this site, including the electronic character of
the Phe4 ring. Finally, pyridine analogs (1j–1l) would present H-bond accepting contacts about the
ring, as well as provide analogs that present dipoles at similar vectors as to previously successful
halogenated substituents.
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2.2. Solid Phase Synthesis of Peptides
All peptides were synthesized using a rapid solid phase peptide synthesis protocol on an automated
peptide synthesizer using an Fmoc protection strategy [34,35] and N,N′-diisopropylcarbodiimide and
oxyma as the coupling reagents (Figure 3B). Fmoc-Leu-Wang resin was utilized as a starting template
for this synthetic protocol. All coupling steps and Fmoc-deprotection steps were carried out at 70 ◦C
under an atmosphere of N2. Cleavage from the resin was performed using TFA/triisopropylsilane/H2O.
Purification of the synthesized peptides was performed by reverse-phase high performance liquid
chromatography (RP-HPLC), and analysis of purity was performed using ultra-performance liquid
chromatography (UPLC). All desired peptides were obtained in ≥95% purity before submitting for
pharmacological evaluation.
2.3. Pharmacological Characterization
To characterize our substituted analogs, we assessed binding affinity by competition radioligand
binding, G protein potency and efficacy using a cAMP GloSensor assay and β-arrestin 2 recruitment
via PathHunter assays at both the δOR and µOR. Using Leu5-enkephalin as well as DAMGO (for µOR),
as reference compounds, substitution of the meta position of Phe4 (1a–1i) generally increased binding
affinity for the δOR (Table 1, Ki = 0.023–0.93 nM; Leu5-enkephalin = 1.26 nM) and µOR (Ki = 0.059–0.98
nM; Leu5-enkephalin = 1.7 nM). The improved binding affinity correlated with improved functional
activation of the G protein pathway at both the δOR and µOR, while providing near-full agonist activity
at the δOR (Table S1, 92–100% efficacy) relative to Leu5-enkephalin, and mostly near-full agonist
activities at the µOR (Table S1, 85–105% efficacy; Leu5-enkephalin = 100% efficacy vs. DAMGO).
At the δOR, meta-substituted analogs recruitedβ-arrestin 2 with a range of potencies (Table 2, EC50:
0.56–49 nM; Leu5-enkephalin = 8.9 nM) with near-full efficacies (Table 2, 91–130%; Leu-enkephalin =
100%), and likewise at the µOR, analogs recruited β-arrestin 2 with a broad range of potencies (Table 2,
EC50: 36–589 nM; Leu-enkephalin = 977 nM) and efficacies (Table 2, 60–96% relative to DAMGO;
Leu-enkephalin = 60%; Figure 4). Interestingly, DADLE recruited β-arrestin 2 more efficaciously than
Leu5-enkephalin at both δOR (126%) and µOR (99%). Picoline analogs 1j–1l, generally showed reduced
affinity at both receptors (Table 1, δOR Ki = 6.2–33 nM; µOR Ki = 9–158 nM), which further correlated
with decreased G protein activation of the receptors (Table 2, δOR IC50 = 4.6–48 nM; µOR IC50 =
41–302 nM). At the δOR, the low affinity of pyridyl-substituted analogs correlated with low β-arrestin
2 recruitment (Table 2, EC50 = 100–1122 nM; 84–98% efficacy), though these substitutions drastically
affected β-arrestin 2 recruitment though the µOR (Table 2, EC50 = 1.3–41.6 µM; 36–70% efficacy).
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1a (F) 9.48 ± 0.1 0.33 9.12 ± 0.4 0.76 2.3
1b (Cl) 9.87 ± 0.1 0.13 10.14 ± 0.2 0.072 0.55
1c (Br) 10.35 ± 0.2 0.045 9.90 ± 0.3 0.13 2.9
1d (I) 10.64 ± 0.2 0.023 9.86 ± 0.5 0.14 6.1
1e (Me) 9.86 ± 0.1 0.14 9.86 ± 0.1 0.14 1.0
1f (OMe) 9.31 ± 0.1 0.49 9.07 ± 0.1 0.85 1.7
1g (CF3) 9.93 ± 0.1 0.12 10.23 ± 0.3 0.059 0.49
1h (CN) 9.17 ± 0.3 0.68 9.52 ± 0.1 0.30 0.44
1i (NO2) 9.03 ± 0.2 0.93 9.01 ± 0.1 0.98 1.05
1j (2-pyr) 8.21 ± 0.1 6.17 8.04 ± 0.2 9.12 1.5
1k (3-pyr) 7.48 ± 0.1 33.1 6.80 ± 0.1 158 4.8
1l (4-pyr) 7.69 ± 0.1 20.4 7.41 ± 0.1 38.9 1.9
DADLE 9.01 ± 0.1 0.98 8.80 ± 0.1 1.58 1.6
Leu5-enkephalin 8.90 ± 0.1 1.26 8.77 ± 0.1 1.70 1.3
DAMGO - - 9.01 ± 0.1 0.98 -
All compounds were tested in three independent trials.
Table 2. Meta-substituted Phe4 Analogs of Leu5-enkephalin Display Enhanced δOR and µOR Potency































1a (F) 9.47 ± 0.2 0.39 8.10 ± 0.2 7.94 8.01 ± 0.2 9.77 107 ± 9 6.24 ± 0.1 575 75 ± 13
1b (Cl) 10.66 ± 0.3 0.022 7.52 ± 0.1 30.2 8.77 ± 0.2 1.70 130 ± 10 7.17 ± 0.2 67.6 96 ± 8
1c (Br) 10.52 ± 0.3 0.030 8.00 ± 0.4 10 9.25 ± 0.2 0.56 116 ± 7 7.45 ± 0.2 35.5 79 ± 6
1d (I) 10.61 ± 0.2 0.025 8.37 ± 0.3 4.27 8.95 ± 0.2 1.12 111 ± 7 7.33 ± 0.2 46.8 70 ± 3
1e (Me) 10.41 ± 0.3 0.039 8.43 ± 0.3 3.72 8.46 ± 0.2 3.46 105 ± 5 6.73 ± 0.2 186 71 ± 3
1f (OMe) 9.84 ± 0.3 0.14 8.09 ± 0.3 8.12 7.93 ± 0.2 11.7 106 ± 5 6.23 ± 0.1 589 67 ± 3
1g (CF3) 9.97 ± 0.4 0.11 8.61 ± 0.4 2.45 8.39 ± 0.2 4.07 108 ± 9 7.25 ± 0.2 56.2 71 ± 3
1h (CN) 9.46 ± 0.3 0.35 7.92 ± 0.3 12.0 7.77 ± 0.2 17.0 91 ± 5 6.8 ± 0.2 158 68 ± 4
1i (NO2) 9.33 ± 0.3 0.47 7.31 ± 0.4 49.0 7.31 ± 0.2 49.0 96 ± 6 6.27 ± 0.1 537 60 ± 6
1j (2-pyr) 8.34 ± 0.2 4.57 7.39 ± 0.4 40.7 7.00 ± 0.2 100 92 ± 13 5.87 ± 0.1 1349 70 ± 4
1k (3-pyr) 7.32 ± 0.2 47.9 6.63 ± 0.4 234 5.95 ± 0.1 1122 85 ± 6 4.38 ± 0.1 41687 36 ± 7
1l (4-pyr) 7.52 ± 0.2 30.2 6.52 ± 0.3 302 6.40 ± 0.2 398 98 ± 6 4.43 ± 0.1 37153 64 ± 11
DADLE 9.09 ± 0.2 0.81 7.45 ± 0.1 35.5 7.92 ± 0.4 12.0 126 ± 10 6.33 ± 0.1 468 99 ± 3
Leu5-enkephalin 8.99 ± 0.1 1.02 7.34 ± 0.2 45.7 8.05 ± 0.1 8.91 100 6.01 ± 0.1 977 61 ± 3
DAMGO 5.91 ± 0.2 1230 7.82 ± 0.1 15.1 <5 - 6.80 ± 0.1 158 100
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−bromination, or −iodination (1b–1d) produced high-affinity analogs of Leu5-enkephalin that super-
recruited β-arrestin 2 and that drastically increased functional selectivity (Table 3). These increases 
in affinity at δOR linearly correlate (R2 = 0.998) with the atomic van der Waals radii (H, 1.20 Å; Cl, 
1.77 Å; Br, 1.92 Å; I, 2.06 Å) [36], and might suggest a halogen bonding interaction similar to those 
previously explored at the ortho position of Phe4 [28]. However, the distinct vectors at which a sigma-
hole would present from the ortho vs. meta positions suggest that the specific residues engaged 
through meta-substitution are likely distinct from those previously identified through ortho-
substitution [28], and future computational collaborative work might enable a better understanding 
of the unique binding interactions between the δOR and meta-halogenated analogs of Leu5-
enkephalin. Notably, the meta-chlorinated and −brominated analogs (1b, and 1c) are 500–900-fold 
more potent in cAMP assays at δOR than at µOR, despite exhibiting little differences in binding 
affinity at δOR relative to µOR (Table 1). Interestingly, the meta-Cl analog (1b) had stronger bias 
towards G protein-signaling at δOR (Table 3, bias factor 1.6), but towards β-arrestin 2 recruitment at 
µOR relative to Leu5-enkephalin (Table 3, bias factor 0.004) as well as DAMGO (Table 3, bias factor 
0.3), which provides a unique pharmacological profile for future uses. In contrast, meta-F and −CN 
and −NO2-substitutions (1a,h,i) improved δOR functional selectivity (Table 3), but lost β-arrestin 2 
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(Table 1). Interestingly, the meta-Cl analog (1b) had stronger bias towards G prote n-signaling at δOR
(T ble 3, bi s factor 1.6), but towardsβ-arrestin 2 r cruitment atµOR relative to Leu5-enkephalin (Table 3,
bias factor 0.004) as well as DAMGO (Table 3, bias f ctor 0.3), which pr vides a unique pha macological
profile for future us s. In contr st, meta-F and −CN and −NO2-substitutions (1a,h,i) improved δOR
functional selectivity (Table 3), but lost β-arrestin 2 potency at δOR relative to Leu5-enkephalin.
Additionally, me a-OMe and −NO2 substitution (1f, 1 ) provided both potent and bia ed nalogs,
with G protein coupling activities comparable to Leu5-enkephalin (Table 2, IC50 = 0.14–0.47 nM vs.
1.02 nM), but with improved bias factors relative to Leu5-enkephalin at both δOR (Table 3, bias factor
6.9–7.5) and µOR (Table 3, bias factor 8.4–11.1). Of these two analogs, the -NO2-substituted analog 1i
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exhibited higher δOR functional G protein selectivity (Table 3, 104-fold δOR selectivity) relative to the
−OMe analog 1f (Table 3, 58-fold δOR selectivity). Though pyridyl-substituted analogs (1j–1l) showed
poor potency and efficacy for the δOR and µOR relative to Leu5-enkephalin (Table 2), the 3- and
4-pyridyl analogs (1k–1l) showed strong bias at µOR (Table 3, bias factor 17–331), when compared to
the full agonist DAMGO. However, if instead of DAMGO, Leu5-enkephalin was used as the reference
compound, most analogs, with the exception of 1k and 1l lost G protein bias (Table 3, bias factor < 1),
because the analogs generally were more potent and efficacious than Leu5-enkephalin in recruiting
β-arrestin 2 at µOR (Table 2), with the exception of 1k (Table 2, 36% recruitment efficacy). Given that
exogenous Leu5-enkephalin analogs in vivo would compete with endogenous Leu5-enkephalin and
not DAMGO, our results highlight the limitations of interpreting bias factors (particularly using an
unnatural compound, such as DAMGO, as a reference) and the associated risk of using bias factor as a
major driver of lead optimization.







δOR µOR (DG = Ref) µOR (LE = Ref)
1a (F) 20 1.8 22.2 0.36
1b (Cl) 1372 3.2 0.3 0.004
1c (Br) 333 1.3 1.2 0.02
1d (I) 171 3.5 3.2 0.05
1e (Me) 95 4.3 11.5 0.19
1f (OMe) 58 7.5 8.4 0.14
1g (CF3) 22 2.0 4.3 0.07
1h (CN) 34 6.8 5.4 0.09
1i (NO2) 104 6.9 11.1 0.18
1j (2-pyr) 8.9 4.0 17.2 0.27
1k (3-pyr) 4.9 6.7 331.1 5.89
1l (4-pyr) 10 2.2 63.7 1.08
DADLE 44 0.5 2.3 0.035
Leu5-enkephalin 45 1 4.9 1
DAMGO 0.012 - 1 0.003
Aza-β-homoleucine ¶ 9.9 [23] 5.2 ¶ - 1.2
Rubiscolin-5 - 2.0 [22] - -
¶ from reference 26 using BRET (β-arrestin 2) and EPAC (cAMP) assays. DG = DAMGO, LE = Leu5-enkephalin.
Compared to DADLE, the Leu5-enkephalin analogs 1b and 1c displayed a similar signaling bias
profile, but were more potent and selective for δOR, and thus may provide a better tool compound
to target δORs for the treatment of cardiac ischemia. However, compounds 1b and 1c are also more
potent than DADLE at recruiting β-arrestin 2 to µOR, resulting in a lower bias factor (Figure 4).
In contrast, analog 1i has a favorable pharmacology relative to DADLE, with similar selectivity as 1c,
but improved G-protein bias at δOR and µOR relative to DADLE. Given the potential adverse effects
associated with strong µOR-mediated β-arrestin 2 recruitment, analog 1k is potentially useful, as it
exhibited weak β-arrestin 2 recruitment (36% efficacy) and concomitant strong bias factor for G-protein
signaling. However, cAMP potency for 1k at δOR was more than one log unit weaker than DADLE,
and thus it may be necessary further optimize the ligand by increasing δOR potency in the cAMP assay,
while retaining the low µOR β-arrestin 2 recruitment efficacy (Figure 4).
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2.4. Stability
The stability of all compounds to Sprague Dawley rat plasma was assessed to study the influence
of the meta− and picoline/pyridine-substitutions at Phe4 relative to Leu5-enkephalin (Table 4). For this
parent compound, the predominant known routes of metabolism and clearance occur through cleavage
of Tyr1-Gly2 by aminopeptidase N [37,38], and of Gly3-Phe4 by angiotensin converting enzyme [39],
and combined, the plasma metabolism occurs with a half-life (t1/2) of < 10 min. In general, meta
substituted Phe4 analogs exhibited improved plasma stability compared with Leu5-enkephalin with
half-lives typically >20 min. The 3-fluoro derivative (1a) was the most stable analog with a half-life of
82.3 min. From UPLC-mass spectrometry analysis of degradation fragments, meta-substitution did
not greatly impede the proteolysis at the Tyr1-Gly2 site, but instead slowed digestion at the Gly3-Phe4
site (Table 4). Thus, the improved stability of our Phe4-substituted analogs presumably derived from
perturbation/deceleration of angiotensin-converting enzyme activity. Picoline peptides also displayed
improved stability though interestingly, UPLC-mass spectrometry analysis indicated that degradation
of all pyridyl-substituted analogs (1j–1l) predominantly occurred through Tyr1-Gly2 as opposed to
meta-substituted analogs 1a–1i that degraded through cleavage of Gly3-Phe4.
Table 4. Rat Plasma Stability of Leu5-enkephalin and Its Analogs.




1a (F) 82.3 68.0–102.6 Gly-Gly-(meta-F)Phe-Leu (5 min)(meta-F)Phe-Leu (60 min)
1b (Cl) 37.8 26.5–56.6 Gly-Gly-(meta-Cl)Phe-Leu (5 min)(meta-Cl)Phe-Leu (30 min)
1c (Br) 21.5 12.7–38.7 Gly-Gly-(meta-Br)Phe-Leu (5 min)(meta-Br)Phe-Leu (15 min)
1d (I) 13.2 11.4–15.2 Gly-Gly-(meta-I)Phe-Leu (5 min)(meta-I)Phe-Leu (15 min)
1e (Me) 39.5 30.0–53.5 Gly-Gly-(meta-Me)Phe-Leu (5 min)(meta-Me)Phe-Leu (20 min)
1f (OMe) 46.1 30.4–75.6 Gly-Gly-(meta-OMe)Phe-Leu (5 min)(meta-OMe)Phe-Leu (20 min)
1g (CF3) 44.5 35.0–59.1
Gly-Gly-(meta-CF3)Phe-Leu (5 min)
(meta- CF3)Phe-Leu (30 min)
1h (CN) 33.0 24.0–47.0 Gly-Gly-(meta-CN)Phe-Leu (5 min)(meta-CN)Phe-Leu (20 min)
1i (NO2) 28.8 16.8–55.8
Gly-Gly-(meta-NO2)Phe-Leu (5 min)
(meta- NO2)Phe-Leu (20 min)
1j (2-pyr) 26.8 15.4–53.7 (2-pyridyl)Ala-Leu (5 min)Gly-Gly-(2-pyridyl)Ala-Leu (30 min)
1k (3-pyr) 54.0 29.0–127.0 (3-pyridyl)Ala-Leu (10 min)Gly-Gly-(3-pyridyl)Ala-Leu (20 min)
1l (4-pyr) 78.1 47.5–165.4 (4-pyridyl)Ala-Leu (10 min)Gly-Gly-(4-pyridyl)Ala-Leu (30 min)
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3. Methods
3.1. Synthetic Chemistry-General Considerations
Unless specified, all chemicals were purchased from commercial sources and used without
further purification. All solvents used for synthesis were of analytical grade and used without further
purification. Proton nuclear magnetic resonance (1H-NMR) spectra, and carbon nuclear magnetic
resonance (13C-NMR) spectra were recorded on a Bruker AVIII 500 AVANCE spectrometer with a
CPDUL cryoprobe (500 and 126 MHz, respectively) or a Bruker DRX 500 spectrometer (500 and 126
MHz, respectively). Fluorine nuclear magnetic resonance (19F-NMR) spectra were recorded on a
Bruker AVIII 500 AVANCE spectrometer with a CPDUL BBFO cryoprobe (376 MHz) or a Bruker DRX
500 spectrometer (376 MHz). Chemical shifts (δ) for protons are reported in parts per million (ppm)
downfield from tetramethylsilane, and are referenced to proton resonance of solvent residual peak in
the NMR solvent (MeOD-d4: δ = 4.87 ppm or DMSO-d6: δ = 2.50 ppm). Chemical shifts (δ) for carbon
are reported in ppm downfield from tetramethylsilane, and are referenced to the carbon resonances of
the solvent residual peak (MeOD-d4: δ = 49.1 ppm or DMSO-d6: δ = 39.52 ppm). 19F-NMR chemical
shifts (δ) are reported in ppm with respect to added internal standard: PhCF3 (δ = −63.72 ppm).
NMR data are represented as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet,
dd = doublet of doublets, t = triplet, q = quartet, sept = septet, m = multiplet), coupling constant in
Hertz (Hz), and integration. Exact mass determinations were obtained by using electrospray ionization
using a time of flight mass analyzer (Waters LCT Premiere).
Peptides were synthesized using an Aapptec Focus XC automated peptide synthesizer coupled
with a heating system using a solid phase peptide synthesis protocol using Fmoc chemistry. Preparative
RP-HPLC was performed using an appropriate column and solvent system (described below) and
final purity of peptides was determined by UV area % from UPLC analysis. Peptides were purified by
Teledyne ISCO EZ Prep system on RediSep® C18 Prep column (30 × 250 mm, 100 Å). Purity analysis of
final peptides was carried out using a Waters UPLC Aquity system equipped with a PDA eλ detector
(200 to 400 nm) and a HSS T3 C18 column, (1.8 µM, 2.1 × 50 mm column), using one of two methods.
Protocol A: gradient elution of 2% MeCN with 0.1% formic acid in H2O to 98% MeCN over 2.5 min,
then holding at 98% MeCN for 3 min at a flow rate of 0.6 mL/min. Protocol B: gradient elution of 2%
MeCN with 0.1% formic acid in H2O to 98% MeCN over 2.5 min, then holding at 98% MeCN for 1 min
at a flow rate of 0.7 mL/min at 40 ◦C. Plasma stability was also assessed using the above UPLC column
and solvent gradient program using a Waters H class Plus Acquity UPLC system coupled with a QDa
detector using protocol B.
3.2. Synthesis of Peptides
Peptides were synthesized using a solid phase peptide synthesis protocol using an Aapptec Focus
XC automated peptide synthesizer coupled with a heating system using the Fmoc chemistry and
Wang resin as solid support [34]. To prepare the resin for synthesis, a reaction vessel equipped with a
sintered glass bottom was charged with Fmoc-Leu-Wang resin (0.2 mM), and swelled in a mixture of
dichloromethane and DMF (1:1) for 15 min. The resin was then transferred to a peptide synthesizer
reaction vessel. The resin was deprotected twice using 20% piperidine in DMF for 5 min at 70 ◦C.
Subsequently, an Fmoc-protected amino acid was double coupled with the Leucine-wang resin by
treating with N,N′-diisopropylcarbodiimide (3.0 equiv., 0.2 M in DMF) and Oxyma (3.0 equiv., 0.2 M in
DMF) at 70 ◦C for 8 min. Completion of coupling reactions was monitored by a Kaiser’s test for the
initial peptide [40]. Each coupling was followed by removal of the Fmoc group using 20% piperidine
in DMF at 70 ◦C for 5 min and repeated once. The cycle of the Fmoc removal and coupling was
repeated with subsequent Fmoc-protected amino acids to generate the desired resin-bound peptide.
Cleavage of the peptide from resin and concomitant deprotection of the side chain protecting groups
was carried out by shaking in TFA/triisopropylsilane/H20 (95/2.5/2.5; 5 mL), at ambient temperature for
3 h. Subsequent filtration afforded the peptide in the filtrate and the volume was reduced to 0.2 mL.
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Then, the crude peptides were precipitated by adding cold diethyl ether, and the crude peptides were
then purified by RP-HPLC. Synthesized peptides were characterized by NMR, and the high-resolution
mass spectroscopy.
3.3. Materials Used in the Cellular Signaling Assays
Leu5-enkephalin and forskolin, were purchased from Sigma-Aldrich (St. Louis, MO USA). (d-Ala2,
N-MePhe4, Gly-ol) enkephalin (DAMGO) was purchased from Tocris Bioscience (Minneapolis, MN,
USA). Radiolabels were from Perkin Elmer (Waltham, MA, USA).
3.4. Cell Culture and Biased Signaling Assays
cAMP inhibition and β-arrestin 2 recruitment assays were performed as previously described [12].
In brief, for cAMP inhibition assays HEK 293 (Life Technologies, Grand Island, NY, USA) cells
were transiently transfected in a 1:3 ratio with FLAG-mouse δOR, or HA-mouse µOR and
pGloSensor22F-cAMP plasmids (Promega, Madison, WI, USA) using Xtremegene9 (Sigma). Two days
post-transfection cells (20,000 cells/well, 7.5 µL) were seeded in low volume Greiner 384-well plates
(#82051-458, VWR, Batavia, IL, USA) and were incubated with Glosensor reagent (Promega, 7.5 µL, 2%
final concentration) for 90 min at room temperature. Cells were stimulated with 5 µL drug solution
for 20 min at room temperature prior to stimulation with 5 µL forskolin (final concentration 30 µM)
for an additional 15 min at room temperature. For β-arrestin recruitment assays, CHO-human µOR
PathHunter β-arrestin 2 cells or CHO-human δOR PathHunter β-arrestin 2 cells (DiscoverX, Fremont,
CA, USA) were plated (2,500 cells/well, 10 µL) one day prior to stimulation with 2.5 µL drug solution
for 90 min at 37 ◦C/5% CO2, after which cells were incubated with 6 µL cell PathHunter assay buffer
(DiscoverX) for 60 min at room temperature as per the manufacturer’s protocol. Luminescence for
each of these assays was measured using a FlexStation3 plate reader (Molecular Devices, Sunnyvale,
CA, USA).
3.5. Radioligand Binding Assay
For the binding assay 50µL of a dilution series of peptide was added to 50µL of 3.3 nM [3H]DPDPE
(Kd = 3.87 nM) or 2.35 nM of [3H]DAMGO (Kd = 1.07 nM) in a clear 96 well plate. Next, 100 µL
of membrane suspension containing 7 µg protein was added to the agonist wells and incubated for
90 min at room temperature. The reaction mixture was then filtered over a GF-B filter plate (Perkin
Elmer) followed by four quick washes with ice-cold 50 mM Tris HCl. The plate was dried overnight,
after which 50 µL scintillation fluid (Ultimagold uLLT) was added and radioactivity was counted on a
Packard TopCount NXT scintillation counter. All working solutions were prepared in a radioligand
assay buffer containing 50 mM Tris HCl, 10 mM MgCl2, and 1 mM ethylenediaminetetraacetic acid at
pH 7.4.
3.6. Calculation of Bias Factor
Bias factors were calculated using the operational model equation in Prism 8 to calculate Log
R (τ/KA) (Table S2) as previously described [12]. Subsequently, bias factors were calculated using
Leu5-enkephalin as reference compound for δOR and using either DAMGO or Leu5-enkephalin as
reference compound for µOR, respectively. Leu5-enkephalin and DAMGO were more potent in the
cAMP (G protein) assay than in the β-Arrestin 2 recruitment assay, and thus were not unbiased,
but rather G protein-biased to begin with. A bias factor > 1 meant that the agonist was more G
protein-biased than the reference compound; A bias factor < 1 meant that the agonist was less G
protein-biased than the reference compound.
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3.7. Data and Statistical Analysis
All data are presented as means ± standard error of the mean, and analysis was performed using
GraphPad Prism 8 software (GraphPad Software, La Jolla, CA). For in vitro assays, nonlinear regression
was conducted to determine pIC50 (cAMP) or pEC50 (β-arrestin 2 recruitment). Technical replicates
were used to ensure the reliability of single values, specifically each data point for binding andβ-arrestin
recruitment was run in duplicate, and for the cAMP assay in triplicate. The averages of each independent
run were counted as a single experiment and combined to provide a composite curve in favor of
providing a ‘representative’ curve. In each experimental run, a positive control/reference compound
was utilized to allow the data to be normalized and to calculate the log bias value. A minimum of
three independent values were obtained for each compound in each of the cellular assays.
3.8. Assessment of Plasma Stability
Sprague Dawley rat plasma containing K2-ethylenediaminetetraacetic acid (Innovative Research,
MI, USA) was transferred into 300 µL aliquots and stored at −20 ◦C until use. The plasma stabilities of
Leu5-enkephalin and its synthesized analogs were determined in plasma diluted to 50% with saline
(isotonic sodium chloride solution; 0.9% w/v) [41]. An aliquot of the resulting solution (25 µL) was
incubated at 37 ◦C for 15 min before the addition of a solution of a Leu5-enkephalin analog (25 µL of a
100 µM isotonic NaCl solution; 0.9% w/v). After adding analog, an aliquot of the mixture was removed
at each indicated time point (0, 5, 10, 15, 20, 30, 60, 120, 240 min) and immediately quenched with
100 µL of a methanol solution containing 20 µM Fmoc-Leu-OH as an internal standard. The resulting
peptide solutions were centrifuged at 13,000 rpm for 15 min at 4 ◦C on tubes equipped with 2000 MW
filtrate tubes (Sartorius, USA). Then, the filtrate was transferred into vials and a 5 µL sample of the
resulting solution was analyzed on an UPLC system coupled with a QDa detector. For quantitative
determination, area-under-the-curve for the peaks corresponding to the UV chromatogram was
measured for both the Leu5-enkephalin analog and the internal standard. Determination of half-life
(t1/2) was carried out by using the GraphPad Prism one-phase decay method.
4. Conclusions
Meta-substitutions of Phe4 of Leu5-enkephalin were generally well tolerated and certain
substitutions improved affinity, potency, δOR selectivity and stability of this endogenous opioid.
The generated pharmacological data herein may aid computational modeling efforts to reveal
ligand-receptor interactions at δOR and µOR that will guide the development of novel peptides
with tuned selectivity and signaling profiles. The novel Leu5-enkephalin analogs have superior δOR
selectivity over µOR relative to DADLE, the gold-standard peptide for studying the role of δOR
in cardiac ischemia. Additionally, the analogs generally have lower β-arrestin recruitment efficacy
at µOR, which could further reduce potential adverse in vivo effects. Finally, relative to DADLE,
the meta-substituents tune the bias profile at δOR (either more or less biased towards G-protein
signaling), and the resulting tool compounds should be useful for investigating the importance of δOR
mediated β-arrestin signaling in the peptides cardioprotective effects.
Supplementary Materials: The following are available online, Specifically, for compounds 1a–l: Additional
pharmacological characterization, stability data, NMR spectra and characterization data for peptides, UPLC traces
for determining purity. Table S1: Efficacy of cAMP inhibition of Meta-substituted Phe4 Analogs of Leu5-enkephalin
at δOR and µOR. Table S2: LogR values for Meta-substituted Phe4 Analogs of Leu-enkephalin at δOR and µOR in
the cAMP and β-arrestin 2 (β-arr2) assays. 95% confidence intervals are presented between parentheses.
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design, synthesis, and analysis of analogs, original draft preparation. H.S. data acquisition and analysis. B.R.C.
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